Cargando…
Phosphodiesterase 4A confers resistance to PGE2‐mediated suppression in CD25(+)/CD54(+) NK cells
Inadequate persistence of tumor‐infiltrating natural killer (NK) cells is associated with poor prognosis in cancer patients. The solid tumor microenvironment is characterized by the presence of immunosuppressive factors, including prostaglandin E2 (PGE2), that limit NK cell persistence. Here, we inv...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926252/ https://www.ncbi.nlm.nih.gov/pubmed/33480074 http://dx.doi.org/10.15252/embr.202051329 |
_version_ | 1783659428673748992 |
---|---|
author | Chen, Ziqing Yang, Ying Neo, Shi Y Shi, Hao Chen, Yi Wagner, Arnika K Larsson, Karin Tong, Le Jakobsson, Per‐Johan Alici, Evren Wu, Jing Cao, Yihai Wang, Kai Liu, Lisa L Mao, Yumeng Sarhan, Dhifaf Lundqvist, Andreas |
author_facet | Chen, Ziqing Yang, Ying Neo, Shi Y Shi, Hao Chen, Yi Wagner, Arnika K Larsson, Karin Tong, Le Jakobsson, Per‐Johan Alici, Evren Wu, Jing Cao, Yihai Wang, Kai Liu, Lisa L Mao, Yumeng Sarhan, Dhifaf Lundqvist, Andreas |
author_sort | Chen, Ziqing |
collection | PubMed |
description | Inadequate persistence of tumor‐infiltrating natural killer (NK) cells is associated with poor prognosis in cancer patients. The solid tumor microenvironment is characterized by the presence of immunosuppressive factors, including prostaglandin E2 (PGE2), that limit NK cell persistence. Here, we investigate if the modulation of the cytokine environment in lung cancer with IL‐2 or IL‐15 renders NK cells resistant to suppression by PGE2. Analyzing Cancer Genome Atlas (TCGA) data, we found that high NK cell gene signatures correlate with significantly improved overall survival in patients with high levels of the prostaglandin E synthase (PTGES). In vitro, IL‐15, in contrast to IL‐2, enriches for CD25(+)/CD54(+) NK cells with superior mTOR activity and increased expression of the cAMP hydrolyzing enzyme phosphodiesterase 4A (PDE4A). Consequently, this distinct population of NK cells maintains their function in the presence of PGE2 and shows an increased ability to infiltrate lung adenocarcinoma tumors in vitro and in vivo. Thus, strategies to enrich CD25(+)/CD54(+) NK cells for adoptive cell therapy should be considered. |
format | Online Article Text |
id | pubmed-7926252 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79262522021-03-12 Phosphodiesterase 4A confers resistance to PGE2‐mediated suppression in CD25(+)/CD54(+) NK cells Chen, Ziqing Yang, Ying Neo, Shi Y Shi, Hao Chen, Yi Wagner, Arnika K Larsson, Karin Tong, Le Jakobsson, Per‐Johan Alici, Evren Wu, Jing Cao, Yihai Wang, Kai Liu, Lisa L Mao, Yumeng Sarhan, Dhifaf Lundqvist, Andreas EMBO Rep Articles Inadequate persistence of tumor‐infiltrating natural killer (NK) cells is associated with poor prognosis in cancer patients. The solid tumor microenvironment is characterized by the presence of immunosuppressive factors, including prostaglandin E2 (PGE2), that limit NK cell persistence. Here, we investigate if the modulation of the cytokine environment in lung cancer with IL‐2 or IL‐15 renders NK cells resistant to suppression by PGE2. Analyzing Cancer Genome Atlas (TCGA) data, we found that high NK cell gene signatures correlate with significantly improved overall survival in patients with high levels of the prostaglandin E synthase (PTGES). In vitro, IL‐15, in contrast to IL‐2, enriches for CD25(+)/CD54(+) NK cells with superior mTOR activity and increased expression of the cAMP hydrolyzing enzyme phosphodiesterase 4A (PDE4A). Consequently, this distinct population of NK cells maintains their function in the presence of PGE2 and shows an increased ability to infiltrate lung adenocarcinoma tumors in vitro and in vivo. Thus, strategies to enrich CD25(+)/CD54(+) NK cells for adoptive cell therapy should be considered. John Wiley and Sons Inc. 2021-01-22 2021-03-03 /pmc/articles/PMC7926252/ /pubmed/33480074 http://dx.doi.org/10.15252/embr.202051329 Text en © 2021 The Authors. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Articles Chen, Ziqing Yang, Ying Neo, Shi Y Shi, Hao Chen, Yi Wagner, Arnika K Larsson, Karin Tong, Le Jakobsson, Per‐Johan Alici, Evren Wu, Jing Cao, Yihai Wang, Kai Liu, Lisa L Mao, Yumeng Sarhan, Dhifaf Lundqvist, Andreas Phosphodiesterase 4A confers resistance to PGE2‐mediated suppression in CD25(+)/CD54(+) NK cells |
title | Phosphodiesterase 4A confers resistance to PGE2‐mediated suppression in CD25(+)/CD54(+) NK cells |
title_full | Phosphodiesterase 4A confers resistance to PGE2‐mediated suppression in CD25(+)/CD54(+) NK cells |
title_fullStr | Phosphodiesterase 4A confers resistance to PGE2‐mediated suppression in CD25(+)/CD54(+) NK cells |
title_full_unstemmed | Phosphodiesterase 4A confers resistance to PGE2‐mediated suppression in CD25(+)/CD54(+) NK cells |
title_short | Phosphodiesterase 4A confers resistance to PGE2‐mediated suppression in CD25(+)/CD54(+) NK cells |
title_sort | phosphodiesterase 4a confers resistance to pge2‐mediated suppression in cd25(+)/cd54(+) nk cells |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926252/ https://www.ncbi.nlm.nih.gov/pubmed/33480074 http://dx.doi.org/10.15252/embr.202051329 |
work_keys_str_mv | AT chenziqing phosphodiesterase4aconfersresistancetopge2mediatedsuppressionincd25cd54nkcells AT yangying phosphodiesterase4aconfersresistancetopge2mediatedsuppressionincd25cd54nkcells AT neoshiy phosphodiesterase4aconfersresistancetopge2mediatedsuppressionincd25cd54nkcells AT shihao phosphodiesterase4aconfersresistancetopge2mediatedsuppressionincd25cd54nkcells AT chenyi phosphodiesterase4aconfersresistancetopge2mediatedsuppressionincd25cd54nkcells AT wagnerarnikak phosphodiesterase4aconfersresistancetopge2mediatedsuppressionincd25cd54nkcells AT larssonkarin phosphodiesterase4aconfersresistancetopge2mediatedsuppressionincd25cd54nkcells AT tongle phosphodiesterase4aconfersresistancetopge2mediatedsuppressionincd25cd54nkcells AT jakobssonperjohan phosphodiesterase4aconfersresistancetopge2mediatedsuppressionincd25cd54nkcells AT alicievren phosphodiesterase4aconfersresistancetopge2mediatedsuppressionincd25cd54nkcells AT wujing phosphodiesterase4aconfersresistancetopge2mediatedsuppressionincd25cd54nkcells AT caoyihai phosphodiesterase4aconfersresistancetopge2mediatedsuppressionincd25cd54nkcells AT wangkai phosphodiesterase4aconfersresistancetopge2mediatedsuppressionincd25cd54nkcells AT liulisal phosphodiesterase4aconfersresistancetopge2mediatedsuppressionincd25cd54nkcells AT maoyumeng phosphodiesterase4aconfersresistancetopge2mediatedsuppressionincd25cd54nkcells AT sarhandhifaf phosphodiesterase4aconfersresistancetopge2mediatedsuppressionincd25cd54nkcells AT lundqvistandreas phosphodiesterase4aconfersresistancetopge2mediatedsuppressionincd25cd54nkcells |